Background Transactive response DNA-binding protein of 43 kDa (TDP-43) proteinopathy in older adults frequently coexists with Alzheimer's disease pathology and hippocampal sclerosis. It is unclear whether there is a link between APOE ε4 and TDP-43 proteinopathy, and the role of APOE ε4 in the association of TDP-43 proteinopathy with hippocampal sclerosis remains to be examined. We investigated the relationships of TDP-43 proteinopathy and hippocampal sclerosis with APOE ε4.
Introduction
Transactive response DNA-binding protein of 43 kDa (TDP-43) proteinopathy is a core pathology of amyotrophic lateral sclerosis and frontotemporal lobar degeneration (FTLD) with TDP-43 (FTLD-TDP), 1 but it is also commonly observed in older adults without these diseases. TDP-43 proteinopathy in older adults has clinical and pathological characteristics distinct from that seen in FTLD-TDP [2] [3] [4] [5] and commonly coexists with hippocampal sclerosis 3,6-8 and Alzheimer's disease pathology (amyloid-β and tau).
this association was no longer significant when TDP-43 proteinopathy was concurrently considered. 3 Because TDP-43 proteinopathy has a large effect on hippocampal atrophy, cognitive decline, and the risk of Alzheimer's disease dementia beyond what can be explained by Alzheimer's disease pathology alone, 4, [9] [10] [11] [12] it is important to understand the relationship of TDP-43 proteinopathy with other neurodegenerative pathologies in older adults.
Genetic risk factors are not subject to reverse causation, because the random assignment of parental genotypes to an individual during conception cannot be affected by post-natal phenotypes; this property is referred to as Mendelian randomisation. 13 Thus, genetic association studies can provide a unique opportunity in examining the relationship between different post-mortem neuropathologies by assessing shared genetic associations between two pathologies. Notably, two previous studies showed that among participants with autopsy-confirmed Alzheimer's disease pathology, APOE ε4 was associated with the presence of comorbid TDP-43 proteinopathy. 10, 12 However, it is unclear whether the link between APOE ε4 and TDP-43 proteinopathy is independent from other APOE-ε4-related pathologies, and the role of the APOE ε4 haplotype in the association of TDP-43 proteinopathy with hippocampal sclerosis remains to be examined.
Therefore, we aimed to investigate the relationship among APOE ε4, TDP-43 proteinopathy, and other APOE-ε4-related proteinopathies, such as amyloid-β, paired helical filament tau, and Lewy body pathology. 14 Subsequently, leveraging Mendelian random isation of APOE ε4, we aimed to investigate whether the relationship between TDP-43 proteinopathy and hippocampal sclerosis was causal. Finally, we aimed to examine the clinical implications of the APOE ε4-TDP-43 proteinopathy association.
Methods

Study design and participants
We did a community-based cohort study using the Religious Orders Study 15 (ROS) and the Rush Memory and Aging Project 16 (MAP). Both ROS and MAP are longitudinal cohort studies of ageing and dementia that enrol older adults without known dementia and collect annual clinical and post-mortem pathological data. ROS launched in 1994, and enrols Catholic priests, brothers, and nuns from more than 40 religious communities across the USA. MAP started in 1997, and targets participants from diverse backgrounds, including continuous-care retirement communities throughout northeastern Illinois and individual homes across the Chicago metropolitan area of the USA. Further details about the participants are available in previous publications 15 , 16 and the Rush Alzheimer's Disease Center Research Resource Sharing Hub. Each participant has
Research in context
Evidence before this study We searched PubMed for articles published before May 1, 2018, with the search term "(TDP-43 OR hippocampal sclerosis) AND (genetic association OR APOE)", yielding 189 articles. We reviewed these studies to summarise previously identified genetic risk loci of transactive response DNA-binding protein of 43 kDa (TDP-43) proteinopathy or hippocampal sclerosis, or both, and to outline the relationship between APOE and TDP-43 proteinopathy. A previous study reported that rs1990622 near TMEM106B, which is a risk variant for frontotemporal lobar degeneration (FTLD) with TDP-43 (FTLD-TDP), is also associated with TDP-43 proteinopathy in older adults without FTLD or amyotrophic lateral sclerosis. Two studies reported higher number of APOE ε4 carriers in participants with Alzheimer's disease pathology and comorbid TDP-43 proteinopathy than in people with Alzheimer's disease pathology without TDP-43 proteinopathy. For hippocampal sclerosis in older adults that is not from epilepsy or FTLD, genetic association studies have identified several risk variants: rs704178 within ABCC9, rs5848 near GRN, rs1990622 near TMEM106B, and rs9637454 within KCNMB2. By contrast, multiple studies have reported that APOE haplotypes are not associated with hippocampal sclerosis in older adults.
Added value of this study
To our knowledge, this study is the first to report the independent association of APOE ε4 with the presence and severity of TDP-43 proteinopathy, taking into account other APOE ε4-related proteinopathies (Alzheimer's disease pathology and Lewy body pathology), in large community-based cohorts of older adults. We also report that the independent APOE ε4-TDP-43 proteinopathy association is not moderated by other APOE ε4-related proteinopathies. Our results indicate that the association of APOE ε4 with hippocampal sclerosis is largely mediated through TDP-43 burden, reinforcing previous literature that suggests TDP-43 proteinopathy is a central component in the pathological cascade leading to hippocampal sclerosis. Finally, we observed that TDP-43 proteinopathy could contribute to the detrimental effect of APOE ε4 on late-life cognition, beyond Alzheimer's disease pathology.
Implications of all the available evidence
Multiple neurodegenerative pathologies commonly coexist in the ageing brain and synergistically contribute to cognitive decline and dementia. APOE ε4 is associated with an increased risk of multiple major neurodegenerative proteinopathies associated with cognitive decline in older adults (amyloid-β, paired helical filament tau, α-synuclein, and TDP-43). Also, accumulating evidence suggests that hippocampal sclerosis is a pathological condition downstream of TDP-43 proteinopathy. Thus, beyond their common coexistence, major neurodegenerative proteinopathies in older adults might share common pathogenic pathways, a potentially important point to consider in future clinical trials and translational research.
For the Resource Sharing Hub see https://www.radc.rush.edu/ signed a written informed consent and a written Anatomical Gift Act document at the time of enrolment, and the data collection and usage protocols of ROS and MAP have been approved by the Rush University Medical Center Institutional Review Board.
Procedures
To determine cognitive phenotypes, a battery of cognitive tests including the Mini-Mental State Examination and 19 other tests examining multiple cognitive domains was given to ROS-MAP participants each year (appendix), [15] [16] [17] and an annual global cognitive function for each participant was derived by averaging Z scores of these tests, excluding the Mini-Mental State Examination. [15] [16] [17] Subsequently, the random slope of global cognition was derived from linear mixed models with annual global cognitive function as the longitudinal outcome, adjusting for age at baseline, sex, and years of education. 18 The final clinical diagnosis was assigned after death by a neurologist using all available clinical data without access to post-mortem pathology, 15, 16 and individuals with probable Alzheimer's disease dementia (ie, Alzheimer's disease with no other cause of cognitive impairment) or possible Alzheimer's disease dementia (ie, Alzheimer's disease with other cause contributing to cognitive impairment) were considered to have Alzheimer's disease dementia.
Codons 112 and 158 from APOE exon 4 were sequenced to derive APOE haplotypes (ε2, ε3, or ε4). 19 We derived genotype dosage of TMEM106B rs1990622
A , a known TDP-43 proteinopathy risk allele, 5, 20 as previously reported (appendix). 21, 22 Neuropathological evaluation was done as previously reported. 15, 16 Hippocampal sclerosis was evaluated in a coronal section of the mid-hippocampus at the level of the lateral geniculate body, and was recorded as present if there was a severe neuronal loss and gliosis in the CA1 sector or subiculum, or both, generating a binary variable. 3 Hippocampal sclerosis was diagnosed independent of coexisting Alzheimer's disease pathology or TDP-43 proteino pathy, but the diagnosis was not considered in the cases with hippocampal changes related to FTLD or gross or microscopic infarcts. Presence of one or more gross chronic cerebral infarcts was recorded as a binary variable (ie, present or absent).
15,16
Statistical analysis
ROS and MAP were combined in our analyses, because both cohorts capture common clinical and pathological measures and are managed by the same team of investigators, who designed both studies. 15, 16 All regression analyses were controlled for sex and age at death. We excluded participants with missing values.
After observing a correlation between two semiquantitative measures of TDP-43 burden (cytoplasmic inclusion and dystrophic neurites; Spearman's ρ=0·96; p<2·2 × 10 -¹⁶), we chose to use the TDP-43 cytoplasmic inclusion burden for the TDP-43 burden analyses. We estimated the general population prevalence of APOE ε4 haplotype in individuals of European descent See Online for appendix from the allele frequency of rs429358 T in the 1000 Genome Project European population. 24 The asso ciation of APOE ε4 count (continuous ordinal variable values of 0, 1, or 2; independent variable) with TDP-43 proteinopathy stage (outcome variable) was examined with multivariate ordinal logistic regression (R MASS package), and the association of APOE ε4 count (independent variable) with TDP-43 burden (outcome variable) was assessed with multivariate linear regression. Effect of each APOE genotype (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε4, and ε4/ε4) on TDP-43 burden was compared with the reference APOE ε3/ε3 homozygotes, as detailed in the appendix. Additional analyses controlling for amyloid-β, paired helical filament tau, and Lewy bodies were done, and we also assessed whether age at death or other proteinopathies modified the APOE ε4-TDP-43 proteinopathy association by including interaction terms. We used square-root transformed values of the quantitative amyloid-β and paired helical filament tau variables to account for their positively skewed distributions. APOE ε4 count and rs1990622 A dosage were analysed for their statistical interaction in increasing TDP-43 proteinopathy. The association between APOE ε4 and hippocampal sclerosis was assessed with logistic regression without and with adjustment of TDP-43 proteinopathy to examine whether TDP-43 proteinopathy explains this association.
We also did a mediation analysis with APOE ε4 carrier status as an independent causal variable, TDP-43 burden as a mediator, and hippocampal sclerosis as a binary outcome, and the mediated effect and direct effect were estimated with the default quasi-Bayesian Monte Carlo method and bootstrap simulation from the R mediation package. 25 Finally, the residual association of APOE ε4 count with global cognitive function proximate to death (continuous variable; linear regression) or Alzheimer's disease dementia (binary variable; logistic regression) was evaluated after controlling for amyloid-β, paired helical filament tau, age at death, sex, and years of education; we added TDP-43 proteinopathy to these models as a covariate to assess whether TDP-43 proteinopathy explains this residual effect of APOE ε4 on cognition and dementia. To assess clinical characteristics of each sub group defined by TDP-43 proteinopathy stage, hippocampal sclerosis, and APOE ε4 carrier status, we defined advanced TDP-43 proteinopathy as stages 2 and 3, the stages that are associated with increased odds of dementia. 9 Residual global cognitive decline (or residual global cognitive function) was defined as the residual from a linear model having the random slope of global cognition (or global cognitive function proximate to death adjusted for sex, age at death, and years of education) as the outcome and amyloid-β and paired helical filament tau as predictors. Further details on the covariate selection procedure, power calculation for subgroup analyses, and mediation analyses are described in the appendix.
We did all statistical analyses using R (version 3.3).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit for publication. The first and corresponding authors had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit this manuscript for publication. Odds ratios of higher TDP-43 proteinopathy stage as APOE ε4 count increased were reported from ordinal logistic regressions with TDP-43 proteinopathy stage (0-3) as an outcome, and estimated effects (adjusted increase in TDP-43 burden as APOE ε4 count increased) were reported from linear regressions with a semi-quantitative TDP-43 burden (range 0-5) as an outcome. Model 1 is the primary analysis, and has APOE ε4 count as the independent variable and TDP-43 proteinopathy stage or burden as the outcome. Models 2 and 3 also have APOE ε4 count as the independent variable, and adjust for other APOE ε4-related proteinopathies. Model 4 tests whether the interaction term between APOE ε4 count and the pathological diagnosis of Alzheimer's disease is associated with TDP-43 proteinopathy stage or burden. Model 5 tests whether any of the interaction terms between APOE ε4 count and amyloid-β, paired helical filament tau, or Lewy body pathology stage is associated with TDP-43 proteinopathy stage or burden. All analyses were adjusted for sex and age at death. TDP-43=transactive response DNA-binding protein of 43 kDa. *n=1044 for TDP-43 proteinopathy stage as the outcome, and n=1027 for TDP-43 burden as the outcome. †n=1042 for TDP-43 proteinopathy stage as the outcome, and n=1025 for TDP-43 burden as the outcome (two participants had missing values for Lewy body pathology). The APOE ε4-TDP-43 proteinopathy association was only partially attenuated after controlling for amyloid-β, paired helical filament tau, and Lewy body pathology (table 2) . Conversely, the associations of APOE ε4 with other proteinopathies were not fully explained by TDP-43 proteinopathy (appendix). A logistic regression analysis confirmed the independent association between TDP-43 proteinopathy and APOE ε4 (appendix). Furthermore, diagnosis of Alzheimer's disease pathology or Lewy body pathology burden did not show significant interaction with the APOE ε4 count (table 2), suggesting no strong evidence that the effect of APOE ε4 count on TDP-43 proteinopathy varies with Alzheimer's disease or Lewy body pathological burden. We did not observe a significant association between APOE ε4 and TDP-43 proteinopathy when we limited our analysis to the subgroup of individuals without a pathological diagnosis of Alzheimer's disease (n=372, with 45 APOE ε4 carriers; appendix). However, this subgroup analysis is underpowered because the APOE ε4 haplotype frequency is lower than in the overall study population: we would need approximately 1100 participants without a pathological diagnosis of Alzheimer's disease (appendix) to show the same APOE ε4-TDP-43 proteinopathy association that was observed in the subgroup with a pathological diagnosis of Alzheimer's disease. Clinical and pathological characteristics of these subgroups are shown in the appendix.
Results
ROS
In the logistic regression models, APOE ε4 count was associated with hippocampal sclerosis (OR 2·1 as APOE ε4 count increased, 95% CI 1·4-3·0, p=1·7 × 10 -⁴), even when amyloid-β, paired helical filament tau, and Lewy body pathology were adjusted for, but this association was no longer significant when TDP-43 proteinopathy was considered (appendix). Because there are strong associations between APOE ε4 and TDP-43 proteinopathy, and TDP-43 proteinopathy and hippocampal sclerosis, TDP-43 proteinopathy could be a mediator of the asso ciation between APOE ε4 and hippocampal sclerosis (appendix). By contrast, hippo campal sclerosis is unlikely to be a strong mediator of the APOE ε4-TDP-43 pro teinopathy association, because the association between APOE ε4 count and TDP-43 proteinopathy was still strong after controlling for hippocampal sclerosis (appendix). On the basis of a causal mediation analysis with the quasi-Bayesian Monte Carlo method, the effect of APOE ε4 carrier status on hippocampal sclerosis was largely mediated by TDP-43 burden (mediated effect p<1·0 × 10 -⁴), whereas the direct effect of APOE ε4 on hippocampal sclerosis independent from TDP-43 burden was not significant (direct effect p=0·40; figure 2) . A non-parametric bootstrap method yielded a similar result, and a sensitivity analysis further supported validity of our result (appendix).
APOE ε4 count was associated with worse global cognitive function proximate to death and higher odds of Alzheimer's disease dementia, and nominal residual associations were observed even after adjusting for Alzheimer's disease pathology (amyloid-β and paired helical filament tau; estimated effect -0·18, 95% CI -0·31 to -0·04; p=0·010; table 3). TDP-43 proteinopathy stage (estimated effect -0·13, 95% CI -0·27 to -0·001; p=0·048) and TDP-43 burden (-0·09, -0·22 to 0·04; p=0·18) attenuated this residual association (table 3) . Adjusted global cognitive decline and adjusted global cognition proximate to death for each subgroups defined by the presence of advanced TDP-43 proteinopathy (stage 2 or 3), hippocampal sclerosis, and APOE ε4 carrier status are shown in table 4. We noted that the subgroup with both advanced TDP-43 proteinopathy and hippocampal sclerosis had the highest proportion of APOE ε4 carriers, highest TDP-43 burden, and the worst cognitive trajectory (adjusted for amyloid-β, paired helical filament tau, and sex, age at death, and years of education; the appendix shows cognitive measures in each subgroup only adjusted for sex, age at death, and years of education).
Discussion
In this study of more than 1000 well characterised older adults from community-based cohorts, we found that 1025 participants with non-missing values were used for this analysis. The average causal mediation effect estimate (ie, the effect of the independent variable to the outcome through the mediator, solid arrows) was significant. By contrast, the average direct effect estimate (ie, the effect of the independent variable to the outcome that is independent from the mediator, dotted arrows) was not significant. (B) The x-axis denotes the size of effect measured by increased probability of the outcome (hippocampal sclerosis), expressed in a relative scale. A filled circle and solid line indicate the effect and 95% CI in the treatment group (ie, APOE ε4 carriers), and an empty circle and dotted line indicate the effect and 95% CI in the control group (ie, APOE ε4 non-carriers). Estimated average causal mediation effect and average direct effect were reported separately for APOE ε4 carriers and non-carriers in this simulation, as the outcome model was non-linear. The plot shows no significant difference between APOE ε4 carriers and non-carriers in their estimated average causal mediation effect or average direct effect. About 70% of the total effect is through the average causal mediation effect. All models were adjusted for sex and age at death. APOE ε4 is a strong genetic predictor of the presence and severity of TDP-43 proteinopathy. This association was not fully explained or significantly moderated by other APOE ε4-related proteinopathies (amyloid-β, paired helical filament tau, and Lewy body pathology). Furthermore, TDP-43 proteinopathy contributed to poor cognition and increased odds of dementia associated with APOE ε4, which was beyond what could be explained by amyloid-β and paired helical filament tau. Therefore, in addition to amyloid-β, paired helical filament tau, and Lewy body pathology, 14 our results indicate that TDP-43 is another major neurodegenerative proteinopathy linked to APOE ε4, and has an independent contribution to the pleiotropic role of APOE ε4 in late-life dementia. 19, 26 The association between APOE ε4 and TDP-43 proteinopathy adds important insights into the relationship between TDP-43 proteinopathy and Alzheimer's disease: they not only coexist but also share a common genetic risk factor. However, the association between TDP-43 proteinopathy and Alzheimer's disease was not fully explained by APOE ε4 alone. Thus, multiple linking points other than APOE might underlie the intricate relationship among the neurodegenerative proteinopathies in older adults. We note that TDP-43 proteinopathy in older adults is unlikely to be a simple downstream or upstream pathology of Alzheimer's disease, because APOE ε4 had an independent association with TDP-43 proteinopathy or Alzheimer's disease even when the other condition was controlled for.
Notably, the effect of APOE ε4 on TDP-43 proteinopathy was independent of and stronger than that of TMEM106B rs1990622 A , a previously reported genetic risk factor of TDP-43 proteinopathy in older adults and FTLD-TDP. 5, 20 Thus, although TDP-43 proteinopathy in older adults shares the TMEM106B-related pathogenic pathway with FTLD-TDP, our result shows that the pathway down stream of APOE might play an independent and more important role in TDP-43 proteinopathy in older adults, supporting that TDP-43 proteinopathy in older adults is a process distinct from FTLD-TDP. Larger studies would be required to confirm these genetic associations, but the association between APOE ε4 and TDP-43 proteinopathy was statistically robust, and exceeded the significance threshold (p<5·0 × 10 -⁸) of an unbiased genome-wide association study.
Our results also provided an important insight into the relationship between TDP-43 proteinopathy and hippocampal sclerosis. TDP-43 proteinopathy might be pathogenically upstream of, or at least precede, most cases of hippocampal sclerosis in older adults, 8 but the causal relationship between two cross-sectional neuro pathological measures has remained elusive. We leveraged Mendelian randomisation 13 to show that TDP-43 proteinopathy is likely to be pathogenically upstream of hippocampal sclerosis in the pathway connecting APOE and hippocampal sclerosis. Therefore, we suggest that TDP-43 proteinopathy in older adults is on a pathogenic continuum with hippocampal sclerosis: most cases of hippocampal sclerosis might represent downstream consequences of TDP-43 proteinopathy-mediated neurodegeneration.
Of note, the association between APOE ε4 and hippocampal sclerosis was not present in multiple previous studies. 7, 14, 27 Although ROS and MAP are volunteer cohorts whose participants do not have dementia at baseline, agreed to future autopsy at study entry, and have sociodemographic differences from the general population, they are community-based cohort studies that have very high rates of follow-up participation and autopsy, minimising biases that affect many large longitudinal studies. These features of the ROS-MAP population might have resulted in a more genetically representative sampling in our study, as shown by the number of participants with an APOE ε4 carrier status that is very close to the estimated general population prevalence, a condition that might have been important to capture the relatively weak association between APOE ε4 and hippocampal sclerosis.
The mechanism of the APOE ε4-TDP-43 proteinopathy association is currently unclear. Besides its well characterised effect on amyloid-β aggregation and clearance, APOE might also affect transport and clearance of other misfolded proteins. There is a Estimated effects (adjusted difference in global cognitive function as APOE ε4 count increased) were reported from linear regressions with global cognitive function proximate to death as the outcome, and odds ratio of Alzheimer's disease dementia as APOE ε4 count increased were reported from logistic regressions with Alzheimer's disease dementia as the outcome. In model 1, APOE ε4 count was the independent variable and sex, age at death, and years of education were controlled. Amyloid-β and paired helical filament tau were additionally controlled in model 2, and Lewy body pathology stage was also controlled in model 3. TDP-43 proteinopathy stage or TDP-43 burden was adjusted in addition to sex, age at death, years of education, amyloid-β, and paired helical filament tau in models 4 and 5, respectively. TDP-43=transactive response DNA-binding protein of 43 kDa. *n=1038 for global cognitive function and n=1033 for Alzheimer's disease dementia. †n=1036 for global cognitive function and n=1031 for Alzheimer's disease dementia. ‡n=1021 for global cognitive function and n=1016 for Alzheimer's disease dementia. suggestion that APOE and TDP-43 form complexes in vivo, thereby aggravating TDP-43 proteinopathy and related neurodegeneration. 28 However, we cannot rule out that toxic amyloid-β or tau oligomers could explain the link between APOE and TDP-43, as neuropathological evaluation through microscopic examination cannot quantify the oligomers present in the tissue.
Our study has several limitations. It is mainly based on highly educated volunteers who were healthy at study entry, and their average age at death was close to 90 years. Although age did not significantly moderate the APOE ε4-TDP-43 proteinopathy association, our findings might not apply to younger individuals or people from other socioeconomic backgrounds. Additionally, the majority of participants from both cohorts were of European descent, so our findings cannot be easily extrapolated to other racial groups. We combined ROS and MAP in our analyses, but these two cohorts consist of participants from different social backgrounds. The difference between the two cohorts did not significantly confound the association between APOE ε4 and TDP-43 proteinopathy in our study, but given the larger effect size of APOE ε4 on TDP-43 proteinopathy in MAP compared with ROS, further studies in independent cohorts are required for a better estimation of the effect size. Finally, we have evaluated only a subset of brain regions known to harbour TDP-43 proteinopathy. 2 Hippocampal sclerosis was evaluated on only a single coronal section of mid-hippocampus from each participant, whereas hippocampal sclerosis can be segmental in appearance; 29 therefore, we might have misclassified some cases of hippocampal sclerosis, underestimating the strength of association between TDP-43 proteinopathy and hippocampal sclerosis.
Despite these limitations, our study leveraged the largest TDP-43 proteinopathy dataset reported to date to add important insights to the relationships among Alzheimer's disease, TDP-43 proteinopathy, and hippocampal sclerosis through a shared genetic risk factor, APOE ε4. Beyond classic one-to-one clinical-pathological correlations, it has been well known that coexistence of multiple neuropathologies is the rule rather than an exception in late-onset dementia. 9 Our results suggest that such coexistence is not a coincidence: Alzheimer's disease and TDP-43 proteinopathy share APOE as a common risk gene, which implies further mechanistic link between them. Therefore, future clinical trials and translational investigations should consider TDP-43 proteinopathy as an integral component of APOE-related neurodegeneration, and assess TDP-43 proteinopathy whenever possible.
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